Nkarta to Participate in an Upcoming Investor Conference
Nkarta to Participate in an Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
加利福尼亞州南舊金山，2024年11月26日（GLOBE NEWSWIRE）——開發工程自然殺傷（NK）細胞療法的生物製藥公司Nkarta, Inc.（納斯達克股票代碼：NKTX）今天宣佈參加以下投資者會議：
7th Annual Evercore HealthCONx Conference
December 4, 2024
2:10 p.m. ET – fireside chat
第七屆年度Evercore HealthConx會議
2024年12月4日
美國東部時間下午 2:10 — 爐邊聊天
A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, , and a replay will be archived on the website for approximately 90 days.
該活動的同步網絡直播將在Nkarta網站的 「投資者」 欄目上播出，重播將在網站上存檔約90天。
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at .
Nkarta 簡介
Nkarta是一家處於臨床階段的生物技術公司，致力於開發異基因、現成的自然殺傷（NK）細胞療法。通過將其細胞擴增和冷凍保存平台與專有的細胞工程技術和基於CRISPR的基因組工程能力相結合，Nkarta正在建立未來細胞療法產品線，這些療法專爲深度治療活性而設計，旨在爲門診治療環境中的廣泛普及而設計。欲了解更多信息，請訪問該公司的網站。
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
Nkarta 媒體/投資者聯繫方式：
格雷格·曼
Nkarta, Inc.
gmann@nkartatx.com
